Open Forum Infectious Diseases最新文献

{"title":"Prescribing Patterns of High Opioid and Antibiotic Prescribers, Washington State, 2021: Do Some Prescribers Have Trouble Saying No?","authors":"David Trey Evans, Katarina Kamenar, Jessica Zering, Marisa D'Angeli, Erica J Stohs","doi":"10.1093/ofid/ofae657","DOIUrl":"10.1093/ofid/ofae657","url":null,"abstract":"<p><p>Among Washington State emergency and family medicine physicians, high prescribers of opioids were 2.9 times more likely to be high prescribers of antibiotics in the Medicare Part D population. The inverse relationship showed the same association. Antimicrobial and opioid stewards should collaborate on shared goals to implement effective interventions.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 12","pages":"ofae657"},"PeriodicalIF":3.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breakthrough Rectal <i>Neisseria gonorrhoeae</i> Infections After Meningococcal B Vaccination: Microbiological and Clinical Features.","authors":"Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Maria Del Carmen Martearena Garcia, Ilaria Mainardi, Caterina Candela, Diana Canetti, Girolamo Piromalli, Nicola Clementi, Roberto Burioni, Antonella Castagna, Silvia Nozza","doi":"10.1093/ofid/ofae562","DOIUrl":"10.1093/ofid/ofae562","url":null,"abstract":"<p><strong>Background: </strong>4CMenB appears to be effective in reducing <i>Neisseria gonorrhoeae</i> (Ng) infections. Aims are to assess factors associated with breakthrough rectal Ng after 4CMenB and evaluate clinical and microbiological characteristics of breakthrough infections compared with before vaccination.</p><p><strong>Methods: </strong>This was a retrospective study of gay, bisexual, and other men who have sex with men (GBMSM) vaccinated with 4CMenB (2 doses) between 2017 and 2023 at the San Raffaele Scientific Institute for Research, Hospitalization and Healthcare (IRCCS San Raffaele Scientific Institute), Milan, Italy, and tested for rectal Ng. Rectal Ng infection is considered breakthrough if it occurs >1 month after the second 4CMenB dose and with positive nucleic acid amplification test (NAAT) result. Follow-up was from July 2017 (first 4CMenB vaccination) to November 2023 (data freeze). Rectal Ng was screened with both NAAT and gonococcal-specific cultures. Characteristics of individuals with or without breakthrough Ng and of Ng infections before or after 4CMenB were compared using Mann-Whitney and χ²/Fisher tests.</p><p><strong>Results: </strong>Overall, 473 GBMSM vaccinated with 4CMenB were included, with a median age (interquartile range) of 43 (37-51) years; 451 of 473 were living with human immunodeficiency virus. The percentage of NAAT-positive rectal Ng swab samples was 76 of 957 (7.7%) after 4CMenB and 51 of 456 (11.1%) before. Breakthrough rectal Ng after baseline were 76 in 57 of 473 people. People with rectal Ng after 4CMenB were younger, more likely to have a previous sexually transmitted infection, and had more sexual partners than those without (all <i>P</i> < .001). Breakthrough rectal Ng infections were less frequently symptomatic (34.2% vs 66.7%; <i>P</i> = .001) and more likely with negative gonococcal-specific culture (55.3% vs 19.6%; <i>P</i> < .001) compared with before vaccination.</p><p><strong>Conclusions: </strong>Breakthrough rectal Ng infections after 4CMenB were 76 in 57/473 people, preferentially identified in GBMSM with higher-risk sexual behaviors, were less often symptomatic, and more often with negative gonococcal-specific cultures, suggesting lower infection virulence.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae562"},"PeriodicalIF":3.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Detection of Norwalk Virus in Saliva Samples From a Controlled Human Infection Model.","authors":"Robert L Atmar, Frederick H Neill, Nicole M Hayes, Antone R Opekun, David Y Graham, Mary K Estes, Sasirekha Ramani","doi":"10.1093/ofid/ofae652","DOIUrl":"10.1093/ofid/ofae652","url":null,"abstract":"<p><p>Following recent reports of norovirus replication in salivary gland cells, we examined whether the prototype norovirus strain, Norwalk virus (GI.1), could be detected in the saliva of 21 experimentally infected persons. Viral RNA was not detected in saliva 2 and 7 days after challenge despite high levels being present in feces.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae652"},"PeriodicalIF":3.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus</i> and Cryptic <i>Aspergillus</i> Species Causing Invasive Infections Tested in the SENTRY Program.","authors":"Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Abigail Klauer, Mariana Castanheira","doi":"10.1093/ofid/ofae532","DOIUrl":"10.1093/ofid/ofae532","url":null,"abstract":"<p><p>The activity of isavuconazole and other triazoles against non-<i>fumigatus</i> (non-AFM) <i>Aspergillus</i> causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and/or internal spacer region/β-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against <i>Aspergillus</i> sections <i>Flavi</i> (n <i>=</i> 122; minimum inhibitory concentration [MIC]_50/90, 0.5/1 mg/L), <i>Terrei</i> (n <i>=</i> 57; MIC_50/90, 0.5/0.5 mg/L), <i>Nidulantes</i> (n = 34; MIC_50/90, 0.12/0.25 mg/L), <i>Versicolores</i> (n <i>=</i> 7; MIC₅₀, 1 mg/L), and <i>Circumdati</i> (n <i>=</i> 2; MIC range, 0.12-2 mg/L). Similar activity was displayed by other triazoles against those <i>Aspergillus</i> sections. Most of the isolates from <i>Aspergillus</i> sections <i>Fumigati</i> (n <i>=</i> 9), <i>Nigri</i> (n <i>=</i> 146), and <i>Usti</i> (n <i>=</i> 12) exhibited elevated MIC values to isavuconazole (MIC_50/90, 2/-, 2/4, and 2/8 mg/L), voriconazole (MIC_50/90, 2/-, 1/2, and 4/8 mg/L), itraconazole (MIC_50/90, 2/-, 2/4, and 8/>8 mg/L), and posaconazole (MIC_50/90, 0.5/-, 0.5/1, and >8/>8 mg/L), respectively. Isavuconazole was active (MIC values, ≤1 mg/L) against <i>Aspergillus parasiticus</i>, <i>Aspergillus tamarii</i>, <i>Aspergillus nomius</i>, <i>Aspergillus nidulans</i>, <i>Aspergillus unguis</i>, <i>Aspergillus terreus</i>, <i>Aspergillus alabamensis</i>, and <i>Aspergillus hortai</i>, while isavuconazole MIC values between 2 and 8 mg/L were observed against cryptic isolates from <i>Aspergillus</i> section <i>Fumigati</i>. Isavuconazole inhibited 96.1% of <i>Aspergillus niger</i> and 80.0% of <i>Aspergillus tubingensis</i> at ≤4 mg/L, the CLSI wild-type cutoff value for <i>A niger</i>. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae532"},"PeriodicalIF":3.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Pneumonia Caused by Gram-Negative Bacteria in Intensive Care Units: Unit-Specific Combination Antibiograms Versus Patient-Specific Risk Factors.","authors":"Walaiporn Wangchinda, Samuel L Aitken, Megan E Klatt, Paul R Lephart, Aaron B Smith, Jason M Pogue","doi":"10.1093/ofid/ofae643","DOIUrl":"10.1093/ofid/ofae643","url":null,"abstract":"<p><strong>Background: </strong>Guidelines suggest dual antipseudomonal therapy for empiric treatment of pneumonia caused by gram-negative bacteria in intensive care unit (ICU) patients. Additionally, consideration of local susceptibility data and patient-specific risk factors for resistance is recommended for selecting optimal empiric regimens. However, data assessing how to best do this are lacking, and it is unclear whether a local susceptibility data-based or a patient-specific risk factor-based approach will better drive appropriate empiric treatment. This study aims to compare these 2 strategies.</p><p><strong>Methods: </strong>This retrospective study was divided into 2 periods. In period I, gram-negative respiratory cultures from ICU patients were used to develop unit-specific combination antibiograms, and individual patient charts were reviewed to assess the impact of risk factors on antimicrobial susceptibility to develop a risk factor-based treatment algorithm. Optimal empiric regimens based on these 2 strategies were then defined. In period II, these regimens were hypothetically applied to patients to compare rates of appropriate empiric therapy and overuse by the 2 methods.</p><p><strong>Results: </strong>Risk factor-based regimens had a higher appropriateness rate compared to regimens derived from antibiograms (89.9% vs 83.7%). Additionally, applying antibiogram-based regimens resulted in a higher prevalence of antibiotic overuse than a patient-specific risk factor-based approach (69.8% vs 40.3%), with excess overuse driven by a higher frequency of unnecessary use of combination therapy.</p><p><strong>Conclusions: </strong>Both strategies provided high rates of appropriateness in empiric antibiotic selection. However, the patient-specific risk factor-based approach demonstrated a higher rate of appropriate therapy and offered advantages in reducing rates of unnecessary combination therapy.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae643"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections.","authors":"Samantha E Jacobs, Vishnu Chaturvedi","doi":"10.1093/ofid/ofae646","DOIUrl":"10.1093/ofid/ofae646","url":null,"abstract":"<p><p>The global burden of invasive fungal disease is substantial and escalating. Combination antifungal therapy (CAF) may improve patient outcomes by reducing development of resistance, improving drug penetration and rate of fungal clearance, and allowing for lower and less toxic antifungal drug doses; yet, increased cost, antagonism, drug-drug interactions, and toxicity are concerns. Clinical practice guidelines recommend antifungal monotherapy, rather than CAF, for most invasive fungal diseases due to a lack of comparative randomized clinical trials. An examination of the existing body of CAF research should frame new hypotheses and determine priorities for future CAF clinical trials. We performed a systematic review of CAF clinical studies for invasive candidiasis, cryptococcosis, invasive aspergillosis, and mucormycosis. Additionally, we summarized findings from animal models of CAF and assessed laboratory methods available to evaluate CAF efficacy. Future CAF trials should be prioritized according to animal models showing improved survival and observational clinical data supporting efficacy and safety.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae646"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome.","authors":"Muluneh Ademe, Yaneth Osorio, Helina Fikre, Desalegn Adane, Tadele Mulaw, Bruno L Travi, Rawliegh Howe, Asrat Hailu, Tamrat Abebe, Peter C Melby","doi":"10.1093/ofid/ofae649","DOIUrl":"10.1093/ofid/ofae649","url":null,"abstract":"<p><strong>Background: </strong>Co-inhibitory receptors (immune checkpoints) regulate activated immune cells. Their expression on T cells can limit host defense. We hypothesized that chronic <i>Leishmania donovani</i> infection in patients with visceral leishmaniasis (VL) leads to expression of co-inhibitory receptors that could be markers of treatment response and clinical outcome.</p><p><strong>Method: </strong>A prospective cohort of 21 subjects with VL (7 with HIV coinfection) and 10 controls was established to measure T-cell expression of co-inhibitory receptors (PD-1, Tim-3, LAG-3, CTLA-4, and TIGIT) by flow cytometry in discarded remnants of diagnostic splenic or bone marrow aspirates and peripheral blood collected before and after treatment. Plasma levels of soluble co-inhibitory proteins (sPD-1, sTim-3, sLAG-3, and sCTLA-4) and selected cytokines were determined by immunoassay.</p><p><strong>Results: </strong>Expression of co-inhibitory receptors in peripheral blood T cells generally reflected findings in spleen and bone marrow aspirates. PD-1 and Tim-3 were upregulated in CD4+ T cells in HIV-negative and HIV-positive subjects with VL compared to controls. CD8+ T cells from HIV-negative subjects with VL displayed a similar pattern. Plasma levels of sPD-1 and sTim-3 were also greater in VL patients than controls. CD8+ and CD4+ T cells coexpressing PD-1 and Tim-3 showed considerable decline with treatment. Mortality in HIV-negative VL patients was associated with increased CD8+ T cells coexpressing Tim-3 and PD-1, triple-positive CD4+ and CD8+ T cells (PD-1⁺Tim-3⁺LAG-3⁺), and elevated sLAG3.</p><p><strong>Conclusions: </strong>Tim-3 and PD-1 expression on CD4+ and CD8+ T cells, and increased plasma sLAG-3, were markers of treatment response and clinical outcome in patients with VL.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae649"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.","authors":"Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, Mark Bloch, Benhur S Cetin, Ener C Dinleyici, Daniel Dražan, Satu Kokko, Susanna Koski, Outi Laajalahti, Joanne M Langley, Mika Rämet, Peter C Richmond, Peter Silas, Bruce Tapiero, Florence Tiong, Mary Tipton, Benita Ukkonen, Betul Ulukol, Maria Lattanzi, Mauro Trapani, Arnold Willemsen, Daniela Toneatto","doi":"10.1093/ofid/ofae638","DOIUrl":"10.1093/ofid/ofae638","url":null,"abstract":"<p><strong>Background: </strong>Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.</p><p><strong>Methods: </strong>In a phase 3 trial, 3651 healthy 10- to 25-year-old participants were randomized 5:5:9:1 to receive 4CMenB (0-6 schedule), 4CMenB (0-2-6 schedule), investigational MenABCWY vaccine, or control MenACWY-CRM vaccine. The primary objectives were to evaluate safety and demonstrate breadth of immune response by enc-hSBA assay against the MenB strain panel using test-based (percentage of samples without bactericidal activity against strains after 4CMenB vs control vaccination) and responder-based (percentage of participants whose postvaccination sera kill ≥70% strains) approaches. Success was demonstrated with 2-sided 97.5% confidence interval (CI) lower limit >65%. Immunogenicity was assessed by traditional hSBA assay against four indicator strains.</p><p><strong>Results: </strong>Breadth of immune response (test-based) was 78.7% (97.5% CI, 77.2-80.1), 81.8% (80.4-83.1), 83.2% (81.9-84.4) for the 0-2, 0-6, and 0-2-6 schedules, respectively, and (responder-based) 84.8% (81.8-87.5), 89.8% (87.2-92.0), and 93.4% (91.2-95.2), respectively. No clinically relevant differences in immunogenicity were observed across schedules. 4CMenB was well tolerated.</p><p><strong>Conclusions: </strong>The 2-dose (0-2, 0-6) 4CMenB schedules met predefined criteria for success for both breadth of immune response endpoints against a diverse MenB strain panel, had comparable immunogenicity, and safety in line with the established 4CMenB safety profile. The 3-dose schedule provided no additional immunological benefit, supporting use of the 4CMenB 0-2 schedule.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae638"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lethal Disseminated Mucorales Infection With Positive Blood Cultures With Purpura Fulminans Complicating Hemophagocytic Lymphohistiocytosis After Chimeric Antigen Receptor T-Cell Therapy.","authors":"Takahiro Matsuo, Sebastian Wurster, Doina Ivan, Rachel Hicklen, Kelly McConn, Kelli A Bagwell, Fareed Khawaja, Roy F Chemaly, Dimitrios P Kontoyiannis","doi":"10.1093/ofid/ofae647","DOIUrl":"10.1093/ofid/ofae647","url":null,"abstract":"<p><p>We report a case of fulminant Mucorales fungemia in a heavily immunosuppressed cancer patient with hemophagocytic lymphohistiocytosis following CD70-targeted chimeric antigen receptor T-cell therapy. Although rare, Mucorales can cause true fungemia in a broad spectrum of hosts, with a range of manifestations from isolated fungemia to fungemia being part of widely disseminated, high-burden infection.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae647"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bundle of the \"Top 10\" Outpatient Parenteral Antimicrobial Therapy Publications in 2023.","authors":"Lindsey M Childs-Kean, Alison M Beieler, Nicolás Cortés-Penfield, Sara C Keller, Christina G Rivera, Keenan L Ryan, Leah H Yoke, Monica V Mahoney","doi":"10.1093/ofid/ofae635","DOIUrl":"10.1093/ofid/ofae635","url":null,"abstract":"<p><p>Outpatient parenteral antimicrobial therapy (OPAT) has become more common in infectious diseases practice settings. Similarly, OPAT-related publications have also increased. The objective of this article was to summarize clinically important OPAT-related publications from 2023. Eighty-one articles were found on initial search, with 52 meeting inclusion criteria. A survey containing the 19 articles that had at least 1 citation was sent to an email listserv of multidisciplinary clinicians with OPAT experience. This article summarizes the \"top 10\" 2023 OPAT articles from the survey results.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae635"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}